RPG Life Sciences Board Recommends ₹24 Dividend, Approves FY26 Results

RPG Life Sciences Ltd's Board of Directors, at its meeting on April 29, 2026, approved the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2026. The Board recommended a dividend of ₹24/- (300%) per equity share of face value ₹8/- for FY 2025-26, subject to shareholder approval at the upcoming AGM. The dividend will be paid within 30 days of such approval. Additionally, Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for five years, and amendments to the Code of fair disclosure for insider trading were approved. The trading window will open 48 hours after the results declaration.